p21(WAF1/CIP1) expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations

Giuseppe Viale, Caterina Pellegrini, Giovanni Mazzarol, Patrick Maisonneuve, Mark L. Silverman, Silvano Bosari

Research output: Contribution to journalArticlepeer-review


Defects in the mechanisms controlling the cell cycle are crucial in cell transformation and/or tumour progression. p21(WAF1/CIP1) is an inhibitor of cyclin-dependent kinases, induced by p53-dependent and p53-independent pathways, which can block progression through the cell cycle. p21(WAF1/CIP1) expression has been investigated immunohistochemically in a series of 191 patients with colorectal cancer of known p53 status. The purpose of the study was two-fold: to assess the relationship between p21(WAF1/CIP1) immunoreactivity and p53 alterations, and to evaluate the prognostic significance of p21(WAF1/CIP1) expression. In 96 carcinomas (51 per cent), p21(WAF1/CIP1) was expressed in over 10 per cent of tumour cells, whereas in 26, p21(WAF1/CIP1) was detected in under 10 per cent of neoplastic cells; 69 tumours lacked p21(WAF1/CIP1) expression. Immunoreactivity was more frequent in tumours of the right colon (p

Original languageEnglish
Pages (from-to)302-307
Number of pages6
JournalJournal of Pathology
Issue number3
Publication statusPublished - 1999


  • Colorectal carcinoma
  • Immunohistochemistry
  • p21(WAF1/CIP1)
  • p53
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'p21(WAF1/CIP1) expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations'. Together they form a unique fingerprint.

Cite this